June 20 2022
COLCA MS provides clinical secondary packaging and temperature-controlled distribution for OSIVAX
A PHASE 2A CLINICAL STUDY OF THE OVX836 INFLUENZA VACCINE
COLCA Medical & Scientific is proud to support Biopharmaceutical company OSIVAX in the context of its OVX836 clinical trial.
COLCA MS, brings all its skills and provides on behalf of OSIVAX for all the secondary clinical packaging as well as the distribution in the European Union and Australia regarding temperature controlled.
OVX836-003 is a Phase 2a, randomized, double-blind, controlled study to evaluate the immunogenicity and safety of one dose of influenza vaccine OVX836.
This study aims to evaluate the immunogenicity and safety of various dose-levels of OVX836 influenza vaccine administered IM, in adults and over 65 years-old elderly.